Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1 Conference call to be held June 2 at 8AM EDT to discuss rusfertide data presented at ASCO Exhibit 99.1 Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 202 ...